Novus Therapeutics to Present at H.C. Wainwright and Cantor Global Investment Conferences
Conferences Details |
||||
Event: |
|
H.C. Wainwright 22nd Annual |
||
Date: |
|
|
||
Time: |
|
|
||
|
|
|
||
Event: |
|
|
||
Date: |
|
|
||
Time: |
|
|
Live webcasts of both presentations can be accessed by visiting the “Events and Presentations” tab of the investor section of the Novus website at http://ir.novustherapeutics.com/events-and-presentations/events. A replay of the webcasts will be archived for 30 days following the conference.
About
Forward-Looking Statements
This press release contains forward‐looking statements that involves substantial risks and uncertainties. Any statements about the company’s future expectations, plans and prospects, including statements about its strategy, future operations, development of its product candidates, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “estimates,” “intends,” “predicts,” “projects,” “targets,” “looks forward,” “could,” “may,” and similar expressions, constitute forward‐looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, although not all forward‐looking statements include such identifying words. Forward‐looking statements include, but are not limited to statements regarding: risks related to market conditions; expectations regarding the timing for the commencement of future clinical trials; expectations regarding the success of clinical trials; the rate and degree of market acceptance and clinical utility of the company’s products; the company’s estimates regarding expenses and cash runway; and the impact of the ongoing coronavirus pandemic. Actual results may differ materially from those indicated by such forward‐looking statements as a result of various factors. These risks and uncertainties, as well as other risks and uncertainties that could cause the company’s actual results to differ significantly from the forward‐looking statements contained herein, are discussed in our quarterly 10-Q, annual 10-K, and other filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20200915006306/en/
asellers@vergescientific.com
301.332.5574
Source: